Agilent completes acquisition of ACEA Biosciences for $250M in cash
Agilent Technologies announced it has completed the acquisition of ACEA Biosciences a developer of cutting-edge cell analysis tools, for $250M in cash. This acquisition brings together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses. ACEA has developed two ground-breaking platforms that are complementary to Agilent's current portfolio. The ACEA xCELLigence RTCA technology is a unique impedance platform for label-free, real-time cellular function measurements used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. This technology is complemented by the introduction in recent years of the NovoCyte and NovoCyte Quanteon portfolio of high performance bench top flow cytometry systems. ACEA also markets a clinical configuration of the NovoCyte platform, currently commercialized in China. This provides a unique opportunity in combination with Agilent's Reagent Partnership business within Agilent's Diagnostics and Genomics Group which provides reagents for flow cytometry. "The Agilent and ACEA teams are united by a common goal to provide the most innovative high-performance solutions for cell analysis," said Todd Christian, Vice President & General Manager of Agilent's Cell Analysis Division. "We are excited for the opportunities we have as a newly combined team to provide the most advanced tools for scientists performing cell analysis workflows." ACEA is Agilent's second acquisition this year in the cell analysis space. In January, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. Cell analysis is a key area of strategic focus for Agilent.